ADHD as Brain Energy Failure and ME/CFS Predisposition
1 Zametkin1990 — Cerebral Glucose Metabolism in ADHD Adults
Full Citation:: Zametkin AJ, Nordahl TE, Gross M, King AC, Semple WE, Rumsey J, Hamburger S, Cohen RM. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. New England Journal of Medicine. 1990;323(20):1361–1366. DOI:: 10.1056/NEJM199011153232001 PMID:: 2233902 Key Findings::
- PET [18F]FDG study: global cerebral glucose metabolism 8.1% lower in ADHD adults (n=25) vs controls (n=50)
- Largest reductions in premotor cortex and superior prefrontal cortex
- Significant hypometabolism in 30 of 60 brain regions examined
- Regions most affected control attention and voluntary motor activityConclusion:: ADHD adults show widespread cerebral glucose hypometabolism, most pronounced in prefrontal and premotor regions. Foundational evidence for ADHD as a brain energy/metabolic deficit disorder. Limitations:: Adults only; task-state (not resting-state) PET; pre-modern diagnostic criteria; no female-matched controls in original design. Certainty:: 0.80 — High. NEJM landmark; extensively replicated conceptually over 30 years.
2 Quadt2024neurodivergentFatigue — ADHD Traits → 2× Fatigue Risk (ALSPAC Longitudinal)
Full Citation:: Quadt L, Csecs J, Bond R, et al. Childhood neurodivergent traits, inflammation and chronic disabling fatigue in adolescence: a longitudinal case-control study. BMJ Open. 2024;14(7):e084203. DOI:: 10.1136/bmjopen-2024-084203 PMID:: 39038862 Key Findings::
- ADHD traits age 7--9 → OR=2.18 (95% CI 1.33--3.56, p=0.002) for chronic disabling fatigue at age 18
- Autism traits → OR=1.78 (95% CI 1.17--2.72, p=0.004)
- IL-6 at age 9 mediated the relationship; pathway independent of depression
- n=4,563 followed to age 18 (ALSPAC birth cohort)Conclusion:: Strongest prospective evidence that neurodivergent traits predict adolescent fatigue, with IL-6-mediated inflammation as a plausible mechanism. Extends and replicates Norris 2017 in same cohort. Limitations:: Screening instruments (not clinical ADHD/autism diagnoses); fatigue outcome is “chronic disabling fatigue,” not full ME/CFS criteria; IL-6 measured at single timepoint age 9. Certainty:: 0.75 — High. Large longitudinal birth cohort; pre-registered; mediation analysis.
3 SaezFrancas2012adhdcfs — ADHD Prevalence in Adult CFS Patients
Full Citation:: Sáez-Francàs N, Alegre J, Calvo N, et al. Attention-deficit hyperactivity disorder in chronic fatigue syndrome patients. Psychiatry Research. 2012;200(2–3):748–753. DOI:: 10.1016/j.psychres.2012.04.041 PMID:: 22648008 Key Findings::
- 29.7% of 158 adult CFS patients had childhood ADHD; 20.9% had persistent adult ADHD
- CFS + ADHD patients showed earlier CFS onset, more anxiety/depression, higher suicide risk
- ADHD severity and depressive symptoms were independent significant predictors of fatigue intensityConclusion:: ADHD is a common and clinically significant comorbidity in CFS; ~30% childhood prevalence figure is the most cited reference for this estimate. Comorbidity worsens prognosis. Limitations:: Cross-sectional; recall bias for childhood ADHD; single specialist CFS clinic (selection bias); Oxford CFS criteria. Certainty:: 0.55 — Medium. Consistent with similar single-centre studies; no large multicentre replication.
4 Yokokura2021D1Rmicroglia — D1R Reduction and Microglial Activation Co-Imaged in ADHD
Full Citation:: Yokokura M, Takedera K, Kazumata K, et al. In vivo imaging of dopamine D1 receptor and activated microglia in attention-deficit/hyperactivity disorder: a positron emission tomography study. Molecular Psychiatry. 2021;26(9):4958–4967. DOI:: 10.1038/s41380-020-0784-1 PMID:: 32439845 Key Findings::
- D1R decreased in anterior cingulate cortex (ACC) in ADHD; correlated with hyperactivity severity
- Activated microglia increased in DLPFC and orbitofrontal cortex; correlated with processing speed and attention deficits
- Positive correlation between D1R reduction and microglial activation unique to ADHD group
- Drug-naive participants; n=24 per group; dual-tracer PETConclusion:: First in vivo co-imaging of dopaminergic deficit and neuroinflammation in the same ADHD subjects. Mechanistically bridges the shared ME/CFS–ADHD pathway through both catecholamine depletion and prefrontal microglial activation. Limitations:: n=24 per group (adequate for PET but limited statistical power); cross-sectional; adults only; causality indeterminate. Certainty:: 0.62 — Medium-High. Mechanistically important; single study; replication needed.
5 Moffitt2015adhdadult — Adult ADHD as Potentially Distinct from Childhood ADHD (Dunedin)
Full Citation:: Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. American Journal of Psychiatry. 2015;172(10):967–977. DOI:: 10.1176/appi.ajp.2015.14101266 PMID:: 25998281 Key Findings::
- 90% of adult ADHD cases (at age 38) had no childhood ADHD diagnosis
- Only 5% of childhood ADHD cases met diagnostic criteria at age 38
- Adult-onset group: no neuropsychological deficits in childhood or adulthood; no polygenic risk for childhood ADHD
- Childhood and adult ADHD diagnoses are "virtually non-overlapping sets"Conclusion:: Challenges the purely neurodevelopmental framing of adult ADHD. If valid, some adult ADHD presentations may represent acquired catecholaminergic dysfunction – potentially post-infectious – rather than lifetime neurodevelopmental disorder. Limitations:: Single New Zealand birth cohort (1972–73); adult ADHD assessed only at one timepoint (age 38); stimulant treatment of childhood cases may suppress adult symptom emergence; findings contested by other cohort studies. Certainty:: 0.70 — High within methodology; but findings remain contested in the field.
6 Williams2025GCH1BH4 — GCH1/BH4 Deficiency and ADHD: The Catecholamine Bottleneck
Full Citation:: Williams GE, Hausman-Cohen S, Sotos M, Gutierrez E, Bilich C, Mueller FW, Jagshi S. The role of GCH1 deficiency and tetrahydrobiopterin in mental health. International Journal of Molecular Sciences. 2025;26(16):8030. DOI:: 10.3390/ijms26168030 PMID:: 40869351 Key Findings::
- GCH1 rs841 homozygous variant associated with ADHD traits including impaired sustained attention and vigilance
- GCH1 is rate-limiting enzyme for BH4 synthesis; BH4 essential cofactor for TH (dopamine/NE), TPH (serotonin), and NOS
- Five case reports: ADHD behaviour improved with low-dose BH4 supplementation (0.088--0.292 mg/kg/day)
- GCH1 variants also associated with depression, anxiety, PMDD, insomnia, autism traitsConclusion:: GCH1 variant → reduced BH4 → impaired dopamine/NE synthesis → ADHD phenotype. Provides mechanistic link between ADHD and ME/CFS via shared BH4 bottleneck (BH4 is also depleted in ME/CFS orthostatic intolerance via oxidative stress). Limitations:: Narrative review; clinical evidence is anecdotal (n=5 case reports only); potential COI (authors affiliated with genomic testing companies); genetic association is weak (single SNP). Certainty:: 0.40 — Low-Medium. Mechanism is biologically sound; clinical evidence is preliminary.
7 Berthier2025cbfadhd — Cerebral Blood Flow in ADHD: Systematic Review
Full Citation:: Berthier J, Endomba FT, Lecendreux M, et al. Cerebral blood flow in attention deficit hyperactivity disorder: a systematic review. Neuroscience. 2025;567:67–76. DOI:: 10.1016/j.neuroscience.2024.11.075 PMID:: 39631658 Key Findings::
- 20 studies (n=1,652 ADHD, n=580 controls): resting-state hypoperfusion in right orbitofrontal gyrus, temporal cortex, basal ganglia, putamen
- Task-state: hyperperfusion in frontal, cingulate, and precuneus regions
- Methylphenidate normalises striatal, thalamic, and precentral blood flow
- Heterogeneous methods (SPECT, ASL, PET, BOLD) but convergent core findingConclusion:: ADHD is characterised by baseline prefrontal-striatal hypoperfusion that normalises with stimulant treatment. Converges with ME/CFS cerebral hypoperfusion literature and supports shared vascular-metabolic vulnerability. Limitations:: High methodological heterogeneity across studies; most underlying studies are small; medication status varies; inconsistent regional specificity. Certainty:: 0.62 — Medium-High for core finding; weaker for specific region claims.
8 Almutairi2024mitoadhd — Mitochondrial Dysfunction and Mitophagy in ADHD
Full Citation:: Almutairi MM, Althekair A, Almutairi F, Alatabani M, Alsaikhan A. Mitochondrial dysfunction and mitophagy in ADHD: Cellular and molecular mechanisms. Saudi Pharmaceutical Journal. 2024;32(12):102212. DOI:: 10.1016/j.jsps.2024.102212 PMC:: PMC11664080 Key Findings::
- Decreased mitochondrial membrane potential and impaired oxidative phosphorylation in ADHD
- NDUFAF2 (Complex I), UCP2, and mitochondrial organization gene variants correlated with reduced respiratory capacity
- Methylphenidate increases Parkin (mitophagy regulator) and reduces ROS
- Monoaminergic gene variants (DAT, DRD4, SERT, NET) interact with mitochondrial dysfunctionConclusion:: Mitochondrial energy failure is a plausible ADHD pathophysiological mechanism, parallel to ME/CFS mitochondrial dysfunction literature. Methylphenidate’s mitochondria-stabilising effects may partly explain its efficacy in both conditions. Limitations:: Narrative review; mostly preclinical (animal models); human mitochondrial evidence in ADHD is limited; no systematic methodology. Certainty:: 0.35 — Low. Mechanistically interesting but human evidence is weak.
9 Fanet2021BH4neuro — BH4 Pathway from Metabolism to Neuropsychiatry
Full Citation:: Fanet H, Capuron L, Castanon N, Calon F, Vancassel S. Tetrahydrobiopterin (BH4) pathway: from metabolism to neuropsychiatry. Current Neuropharmacology. 2021;19(5):591–609. DOI:: 10.2174/1570159X18666200729103529 PMID:: 32744952 Key Findings::
- BH4 is cofactor for TH (dopamine/NE), TPH (serotonin), and all three NOS isoforms
- Inflammatory cytokines paradoxically increase BH4 synthesis but accelerate its oxidation → net monoamine depletion
- Reduced CSF BH4 associated with depression, Parkinson's, Alzheimer's, ADHD, and autism
- BH4 also has direct anti-inflammatory and anti-oxidant functions beyond neurotransmitter synthesisConclusion:: Infection/neuroinflammation → BH4 oxidative depletion → catecholamine deficiency → ADHD-like and ME/CFS symptoms. Mechanistic bridge linking shared inflammatory trigger to shared neurotransmitter deficit. Limitations:: Narrative review; ADHD coverage is brief; neuropsychiatric associations for ADHD are cited but not systematically reviewed. Certainty:: 0.50 — Medium. Core BH4 biochemistry well-established; ADHD-specific evidence is associational.
10 Spanoghe et al. 2026 — Viewpoint Linking Long Covid and AD(H)D via Neuroimmune Dysfunction
Full Citation:: Spanoghe M, Antonacci T, Schneider N, Molmans THJ. Viewpoint: Linking long Covid and AD(H)D through neuroimmune dysfunction: A translational framework proposal for precision medicine. Brain, Behavior, and Immunity. 2026;131:106181. DOI:: 10.1016/j.bbi.2025.106181 PMID:: 41223978 Article Type:: Viewpoint (no primary data) Key Findings::
- Proposes four converging LC--AD(H)D mechanisms: (1) frontal--striatal--hippocampal dysfunction; (2) neuroimmune dysregulation of catecholamine systems; (3) tryptophan--kynurenine dysregulation; (4) mitochondrial bioenergetic defects
- Reports off-label ADHD pharmacotherapy in LC (methylphenidate, guanfacine, low-dose lithium, dexamfetamine) with partial response; PEM and autonomic dysregulation limit use
- Proposes an acquired "neuroimmune-mediated dopaminergic/noradrenergic dysfunction" hypothesis analogous to neuroimmune-mediated depression
- Frames a precision-immunopsychiatry immune-subtyping framework for LC/ADHD stratificationConclusion:: Hypothesis-generating translational framework linking Long Covid and AD(H)D via shared neuroimmune mechanisms of executive dysfunction; proposes mechanism-driven rather than symptomatic treatment. Limitations:: Viewpoint — no primary data; framework is a synthesis of cited primary studies; cited null result (Zemer 2024) acknowledged but not resolved; patient-organization authorship. Certainty:: 0.50 — Medium (framework). Top journal synthesis but hypothesis-generating; no primary data. Population weight 0.85 (Long Covid) → discounted 0.43.
11 Cysique et al. 2023 — Kynurenine Pathway and Post-Acute COVID Cognitive Impairment
Full Citation:: Cysique LA, Jakabek D, Bracken SG, et al. The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC. Annals of Clinical and Translational Neurology. 2023;10(8):1338–1352. DOI:: 10.1002/acn3.51825 PMID:: 37318955 Article Type:: Original research (cohort) Key Findings::
- Kynurenine pathway dysregulation relates to objective cognitive impairment after acute COVID-19
- Correlates with post-acute sequelae (PASC) presentation, including cognitive complaints
- Provides primary human evidence for the kynurenine arm of the LC--ADHD frameworkConclusion:: Supports mechanism (3): overactivated kynurenine metabolism produces neurotoxic metabolites associated with post-COVID cognitive decline. Limitations:: Cohort-specific; tryptophan–kynurenine measures at one timepoint; association not causality. Certainty:: 0.65 — Medium-High. Direct human kynurenine–cognition measure in PASC. Population weight 0.85 (Long Covid) → discounted 0.55.
12 Rassoulpour et al. 2005 — Kynurenic Acid Lowers Striatal Dopamine
Full Citation:: Rassoulpour A, Wu HQ, Ferré S, Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. Journal of Neurochemistry. 2005;93(3):762–765. DOI:: 10.1111/j.1471-4159.2005.03134.x PMID:: 15836634 Article Type:: In vivo microdialysis (rat) Key Findings::
- Nanomolar kynurenic acid concentrations reduce extracellular dopamine in rat striatum
- Establishes a direct biochemical bridge: kynurenine metabolite → lowered dopamineConclusion:: INDIRECT biochemical link: kynurenine dysregulation can suppress dopaminergic tone, mechanistically connecting the kynurenine and catecholamine arms of the framework. Limitations:: Animal model; microdialysis of one region; does not establish clinical relevance to LC/ADHD directly. Certainty:: 0.70 — High (biochemistry), but animal. Population weight 0.50 → discounted 0.35.
13 Sarkar et al. 2010 — Immunoregulatory Role of Dopamine
Full Citation:: Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine: an update. Brain, Behavior, and Immunity. 2010;24(4):525–528. DOI:: 10.1016/j.bbi.2009.10.015 PMID:: 19896530 Article Type:: Review Key Findings::
- Dopamine modulates T-cell, macrophage, and microglial function via D1--D5 receptors
- Bidirectional dopamine--immune crosstalk: immune cells both respond to and produce dopamineConclusion:: Provides mechanistic basis for mechanism (2): neuroimmune dysregulation of catecholamine systems; supports hypodopaminergia reducing immune competence. Limitations:: Review; general biology, not LC/ADHD/ME/CFS-specific. Certainty:: 0.55 — Medium. General biology. Population weight 0.75 → discounted 0.41.
14 Feng & Lu 2021 — Dopamine Immunomodulation in Inflammatory Diseases
Full Citation:: Feng Y, Lu Y. Immunomodulatory effects of dopamine in inflammatory diseases. Frontiers in Immunology. 2021;12:663102. DOI:: 10.3389/fimmu.2021.663102 PMID:: 33897712 Article Type:: Review Key Findings::
- Dopamine shapes T-cell polarization and cytokine balance via dopamine receptors on immune cells
- Dysregulated dopaminergic signaling contributes to inflammatory disease statesConclusion:: Corroborates mechanism (2): neuroimmune dysregulation of dopamine/noradrenaline with T-cell and cytokine imbalance. Limitations:: Review; broad inflammatory-disease focus; not LC/ADHD-specific. Certainty:: 0.60 — Medium-High. General inflammatory biology. Population weight 0.75 → discounted 0.45.
15 Tanaka et al. 2022 — Mitochondrial Impairment and the Kynurenine System
Full Citation:: Tanaka M, Szabó Á, Spekker E, Polyák H, Tóth F, Vécsei L. Mitochondrial impairment: A common motif in neuropsychiatric presentation? The link to the tryptophan–kynurenine metabolic system. Cells. 2022;11(16):2607. DOI:: 10.3390/cells11162607 PMID:: 36010683 Article Type:: Review Key Findings::
- Mitochondrial impairment is a common motif across neuropsychiatric disorders
- The tryptophan--kynurenine metabolic system intersects mitochondrial function (NAD+/quinolinic acid)Conclusion:: Mechanistic bridge between mechanism (3) kynurenine dysregulation and mechanism (4) mitochondrial bioenergetic defects. Limitations:: Review; general neuropsychiatric biology; not LC/ADHD-specific. Certainty:: 0.55 — Medium. General biology. Population weight 0.75 → discounted 0.41.
16 Xu et al. 2025 — Mitochondrial Complex Gene Cluster and COVID Cognitive Decline
Full Citation:: Xu WT, An XB, Chen MJ, et al. A gene cluster of mitochondrial complexes contributes to the cognitive decline of COVID-19 infection. Molecular Neurobiology. 2025;62(6):6869–6883. DOI:: 10.1007/s12035-024-04471-3 PMID:: 39271627 Article Type:: Original research Key Findings::
- COVID-19 infection suppresses a gene cluster of mitochondrial complexes
- Suppression contributes to COVID-related cognitive decline (PASC cognitive arm)Conclusion:: Primary human evidence for mechanism (4): mitochondrial bioenergetic suppression driving cognitive deficits in Long Covid. Limitations:: Gene-expression/association study; mechanism inferred; LC relevance via post-COVID cognitive decline. Certainty:: 0.55 — Medium. Population weight 0.85 (Long Covid cognitive decline) → discounted 0.47.
17 Fesharaki-Zadeh et al. 2023 — Guanfacine + NAC for Long-COVID Cognitive Deficits
(Fesharaki-Zadeh, Lowe, and Arnsten 2023)
Full Citation:: Fesharaki-Zadeh A, Lowe N, Arnsten AFT. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Neuroimmunology Reports. 2023;3:100154. DOI:: 10.1016/j.nerep.2022.100154 Article Type:: Open-label case series Key Findings::
- Guanfacine + N-acetylcysteine reported to improve attention and executive function in Long-COVID cognitive deficits
- Small open-label case series, no control groupConclusion:: Corroborates the off-label ADHD-pharmacotherapy-in-LC arm and the prefrontal noradrenergic (mechanism 1) basis. Limitations:: Small n, open-label, no control; publication is clinical experience, not a trial. Certainty:: 0.45 — Medium (clinical experience). Population weight 0.85 (Long Covid) → discounted 0.38.
18 Krishnan et al. 2022 — Multidisciplinary Approach to Post-COVID Brain Fog
Full Citation:: Krishnan K, Lin Y, Prewitt KRM, Potter DA. Multidisciplinary approach to brain fog and related persisting symptoms post COVID-19. Journal of Health Service Psychology. 2022;48(1):31–38. DOI:: 10.1007/s42843-022-00056-7 PMID:: 35128461 Article Type:: Case series / practice report Key Findings::
- Describes multidisciplinary management of post-COVID brain fog and persisting symptoms
- Cognitive/executive deficits overlap ADHD-like phenomenologyConclusion:: Clinical context for the LC–ADHD brain-fog/cognitive arm and off-label management. Limitations:: Small descriptive series; no controlled data. Certainty:: 0.40 — Medium (clinical). Population weight 0.85 (Long Covid) → discounted 0.34.
19 Koonce & Martin 2024 — Long-COVID and Stimulant Prescribing (US Claims)
Full Citation:: Koonce RM, Martin BC. The association between suspected long-COVID and stimulant prescribing in the United States. Psychiatry Research. 2024;331:115686. DOI:: 10.1016/j.psychres.2023.115686 PMID:: 38142603 Article Type:: Retrospective claims analysis Key Findings::
- Suspected long-COVID associated with increased stimulant prescribing (methylphenidate/amphetamines) in the US
- Consistent with off-label ADHD pharmacotherapy for LC cognitive symptomsConclusion:: Epidemiological corroboration for the off-label stimulant-in-LC arm of the framework. Limitations:: Claims-based; diagnosis/indication not confirmed; cannot infer efficacy. Certainty:: 0.65 — Medium-High (large dataset). Population weight 0.85 (Long Covid) → discounted 0.55.
20 Merzon et al. 2022 — ADHD as a Risk Factor for Long COVID in Youth
Full Citation:: Merzon E, Weiss M, Krone B, et al. Clinical and socio-demographic variables associated with the diagnosis of long COVID syndrome in youth: A population-based study. International Journal of Environmental Research and Public Health. 2022;19(10):5993. DOI:: 10.3390/ijerph19105993 PMID:: 35627530 Article Type:: Population-based cohort Key Findings::
- ADHD associated with increased risk of Long COVID diagnosis in youth (~300,000 population)
- Supports ADHD as a pre-existing risk factor for LCConclusion:: Corroborates the bidirectional LC–ADHD link (ADHD → higher LC risk). Limitations:: Registry/claims-based diagnosis; pediatric population; ADHD recorded pre-infection. Certainty:: 0.60 — Medium-High. Population weight 0.85 (Long Covid, youth) → discounted 0.51.
21 Gimbach et al. 2024 — ADHD Medication Consumption in Europe After COVID-19
Full Citation:: Gimbach S, Vogel D, Fried R, et al. ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? BMC Psychiatry. 2024;24(1):112. DOI:: 10.1186/s12888-024-05505-9 PMID:: 38336744 Article Type:: Multi-country prescribing analysis Key Findings::
- ADHD medicine consumption increased across Europe after COVID-19
- Consistent with both catch-up diagnosis and a possible post-infection trend changeConclusion:: Corroborates increased stimulant use relevant to the LC–ADHD overlap; does not separate causes. Limitations:: Prescribing data only; indication/causality not established. Certainty:: 0.55 — Medium. Population weight 0.85 (post-COVID context) → discounted 0.47.
22 Ferrara et al. 2023 — Direct Correlation Between COVID-19 and ADHD
Full Citation:: Ferrara F, Zavaleta E, Vitiello A, et al. The direct correlation between Covid-19 and attention deficit/hyperactivity disorder (ADHD). European Neuropsychopharmacology. 2023;73:62–64. DOI:: 10.1016/j.euroneuro.2023.04.010 PMID:: 37121166 Article Type:: Viewpoint/letter Key Findings::
- Argues a direct correlation between COVID-19 and new-onset/worsened ADHD
- Aligns with the bidirectional LC--ADHD premiseConclusion:: Opinion supporting the framework premise; no primary data. Limitations:: Viewpoint/letter, no data; non-systematic. Certainty:: 0.40 — Medium (opinion). Population weight 0.85 (Long Covid) → discounted 0.34.
23 Shkalim Zemer et al. 2024 — COVID-19 Had No Independent Effect on ADHD Diagnosis/Treatment (NULL)
Full Citation:: Shkalim Zemer V, Manor I, Weizman A, et al. The influence of COVID-19 on attention-deficit/hyperactivity disorder diagnosis and treatment rates across age, gender, and socioeconomic status: A 20-year national cohort study. Psychiatry Research. 2024;339:116077. DOI:: 10.1016/j.psychres.2024.116077 PMID:: 39053214 Article Type:: National cohort study (20-year, Israel) Key Findings::
- No independent effect of COVID-19 infection on ADHD diagnosis or treatment rates across age, gender, or SES
- Pandemic did not increase ADHD diagnosis/treatment beyond pre-existing trendsConclusion:: NULL result (the framework’s own cited counterpoint): post-COVID ADHD reports may reflect catch-up diagnosis, ascertainment, or symptom overlap rather than infection-driven new onset. Limitations:: Registry/claims-based ADHD; national context (Israel); null result does not exclude a subset with infection-driven symptoms. Certainty:: 0.70 — High (large national cohort), but null. Population weight 0.85 (post-COVID context) → discounted 0.60.